Search research articles
Contact Us
Filters
Showing results (1-10 of 32) with videos related to
Page
of 4
Sort By:
Clinical Therapeutics
|
August 19, 2007
Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers
Zaiqi Wang, Dennis M Grasela, Gopal Krishna
Journal of Clinical Pharmacology
|
October 2, 2007
Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment
Samir K Gupta, Bhavna Kantesaria, Zaiqi Wang
Current Medical Research and Opinion
|
July 3, 2007
Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection
Gopal Krishna, Mark H Gotfried, Kenneth Rolston, et al.
British Journal of Clinical Pharmacology
|
February 28, 2007
Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults
Samir K Gupta, Bhavna Kantesaria, Christopher Banfield, et al.
Drugs in R&D
|
January 26, 2007
Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects
Gopal Krishna, Robert Noveck, Ramon Vargas, et al.
Journal of Clinical Pharmacology
|
March 31, 2007
The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers
Gopal Krishna, James C Kisicki, Steven Olsen, et al.
Pharmacotherapy
|
June 28, 2007
Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers
Gopal Krishna, James C Kisicki, Steven Olsen, et al.
Current Medical Research and Opinion
|
March 16, 2007
Garenoxacin pharmacokinetics in subjects with renal impairment
Gopal Krishna, Diptee Gajjar, Suzanne Swan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
June 21, 2021
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling
Baoyuan Zhang, Yan Zhang, Jiangwei Zhang, et al.
Clinical Pharmacology and Therapeutics
|
June 28, 2002
Effect of St John's wort on the pharmacokinetics of fexofenadine
Zaiqi Wang, Mitchell A Hamman, Shiew-Mei Huang, et al.
Page
of 4
Search research articles
Search
Showing results (1-10 of 32) with videos related to
Sort By:
Page
of 4
Clinical Therapeutics
|
August 19, 2007
Retrospective analysis of electrocardiographic changes after administration of oral or intravenous garenoxacin in five phase I, placebo-controlled studies in healthy volunteers
Zaiqi Wang, Dennis M Grasela, Gopal Krishna
Journal of Clinical Pharmacology
|
October 2, 2007
Multiple-dose pharmacokinetics and safety of desloratadine in subjects with moderate hepatic impairment
Samir K Gupta, Bhavna Kantesaria, Zaiqi Wang
Current Medical Research and Opinion
|
July 3, 2007
Penetration of garenoxacin into lung tissues and bone in subjects undergoing lung biopsy or resection
Gopal Krishna, Mark H Gotfried, Kenneth Rolston, et al.
British Journal of Clinical Pharmacology
|
February 28, 2007
Desloratadine dose selection in children aged 6 months to 2 years: comparison of population pharmacokinetics between children and adults
Samir K Gupta, Bhavna Kantesaria, Christopher Banfield, et al.
Drugs in R&D
|
January 26, 2007
Nasogastric administration of garenoxacin as crushed tablets with and without concomitant enteral feeding in healthy subjects
Gopal Krishna, Robert Noveck, Ramon Vargas, et al.
Journal of Clinical Pharmacology
|
March 31, 2007
The effect of omeprazole on the bioavailability and safety of garenoxacin in healthy volunteers
Gopal Krishna, James C Kisicki, Steven Olsen, et al.
Pharmacotherapy
|
June 28, 2007
Effect of an aluminum- and magnesium-containing antacid on the bioavailability of garenoxacin in healthy volunteers
Gopal Krishna, James C Kisicki, Steven Olsen, et al.
Current Medical Research and Opinion
|
March 16, 2007
Garenoxacin pharmacokinetics in subjects with renal impairment
Gopal Krishna, Diptee Gajjar, Suzanne Swan, et al.
Advanced Science (Weinheim, Baden-Wurttemberg, Germany)
|
June 21, 2021
Focal Adhesion Kinase (FAK) Inhibition Synergizes with KRAS G12C Inhibitors in Treating Cancer through the Regulation of the FAK-YAP Signaling
Baoyuan Zhang, Yan Zhang, Jiangwei Zhang, et al.
Clinical Pharmacology and Therapeutics
|
June 28, 2002
Effect of St John's wort on the pharmacokinetics of fexofenadine
Zaiqi Wang, Mitchell A Hamman, Shiew-Mei Huang, et al.
Page
of 4